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REGULAR ARTICLE

Anticoagulation in cancer-associated thromboembolism with
thrombocytopenia: a prospective, multicenter cohort study
Brian J. Carney,1 Tzu-Fei Wang,2 Siyang Ren,3 Gemlyn George,4 Amer Al Homssi,5 Manila Gaddh,6 Gregory C. Connolly,7
Vinay I. Shah,8 Thomas Bogue,1 Abigail Bartosic,9 Donna Neuberg,3 Lisa Baumann Kreuziger,10 and Jeffrey I. Zwicker,1 on behalf of
the VENUS Network Investigators

Key Points




In patients with
cancer with VTE and
thrombocytopenia,
modiﬁed-dose anticoagulation was
associated with a
lower rate of major
hemorrhage.
In this cohort,
recurrent VTE was not
observed after
initiation of modiﬁeddose anticoagulation.

Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently
encountered in patients with cancer. Therapeutic anticoagulation in the setting of
thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses
suggest the utility of modiﬁed-dose anticoagulation in this population. To assess the incidence of hemorrhage or thrombosis according to anticoagulation strategy, we performed a
prospective, multicenter, observational study. Patients with active malignancy, acute VTE,
and concurrent thrombocytopenia (platelet count ,100 000/mL) were enrolled. The cumulative incidences of hemorrhage or recurrent VTE were determined considering death as a
competing risk. Primary outcomes were centrally adjudicated and comparisons made
according to initial treatment with full-dose or modiﬁed-dose anticoagulation. A total of 121
patients were enrolled at 6 hospitals. Seventy-ﬁve patients were initially treated with fulldose anticoagulation (62%) and 33 (27%) with modiﬁed-dose anticoagulation; 13 (11%)
patients received no anticoagulation. Most patients who received modiﬁed-dose anticoagulation had a hematologic malignancy (31 of 33 [94%]) and an acute deep vein thrombosis
(28 of 33 [85%]). In patients who initially received full-dose anticoagulation, the cumulative
incidence of major hemorrhage at 60 days was 12.8% (95% conﬁdence interval [CI], 4.920.8) and 6.6% (95% CI, 2.4-15.7) in those who received modiﬁed-dose anticoagulation (FineGray hazard ratio, 2.18; 95% CI, 1.21-3.93). The cumulative incidence of recurrent VTE at 60
days in patients who initially received full-dose anticoagulation was 5.6% (95% CI, 0.2-11)
and 0% in patients who received modiﬁed-dose anticoagulation. In conclusion, modiﬁeddose anticoagulation appears to be a safe alternative to therapeutic anticoagulation in
patients with cancer who develop deep vein thrombosis in the setting of thrombocytopenia.

Introduction
Thromboembolism is a frequent complication of cancer. It is the second-leading cause of death in
patients with cancer and is associated with worsened prognosis and quality of life.1,2 Patients with
Submitted 17 August 2021; accepted 29 September 2021; prepublished online on
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cancer diagnosed with venous thromboembolism (VTE) are more
likely to develop recurrent thrombosis and bleeding complications
while on anticoagulation compared with patients with VTE who do
not have an active malignancy.1-4

Based on the available data, it is evident that patients with cancer
who develop acute VTE in the setting of thrombocytopenia are at
increased risk of both hemorrhage and recurrent VTE. However,
prospective, multi-institutional data to inform management in this setting are lacking. We initiated a prospective, observational, multicenter cohort study to assess rates of hemorrhage and recurrent VTE
among patients with cancer, acute VTE, and thrombocytopenia
treated with modiﬁed or therapeutic doses of anticoagulation.

Methods

Study assessments
Study assessments were performed at 30 and 60 days after enrollment and included laboratory studies, review of anticoagulation status and compliance, and assessment for hemorrhage and recurrent
VTE events. Recurrent VTE was objectively conﬁrmed by imaging
studies or documentation. Hemorrhage events (major hemorrhage
and clinically relevant nonmajor bleeding) were classiﬁed according
to International Society on Thrombosis and Haemostasis criteria.13,14 Hemorrhage and recurrent VTE outcomes were centrally
adjudicated by 2 physicians. At each study visit, adherence to the
documented anticoagulation and/or platelet transfusion plans was
assessed and classiﬁed as “excellent” (ie, frequent dose adjustment
based on platelet count or full-dose anticoagulation maintained with
platelet transfusion support), “poor” (ie, anticoagulation not adjusted
based on platelet count or treatment plan not followed more often
than not), or “mixed” by the site investigator.

Statistical analysis
The primary end points of the study were hemorrhage and recurrent
VTE events within 60 days of the initial VTE event (time zero representing the date of the initial VTE). Primary analyses were according
to intention-to-treat based on the initial anticoagulation regimen at
the time of enrollment. No formal sample size was determined, but
there was a target enrollment of 200 patients to provide point estimates of event rates. The study stopped early due to the COVID-19
pandemic resulting in an extended cessation of patient enrollment
across all study sites. Variables were compared between the fulldose, modiﬁed-dose, and no anticoagulation cohorts by using Fisher’s exact test for categorical variables and the Wilcoxon rank sum
test for continuous variables. The method of Kaplan and Meier was
used to estimate survival, and the log-rank test was used to compare survival between the groups. The cumulative incidences of
hemorrhage and recurrent VTE were determined with death considered as a competing risk and sub-hazard ratio calculated by using
the Fine-Gray regression.15 Two-sided P values ,.05 were considered statistically signiﬁcant. Patients who were still alive were censored at the date of last contact. Patients who were discharged to
hospice were considered deceased at the date of last contact.

Study design

Results

A prospective cohort study was conducted at 6 academic hospitals
in the United States through VENUS (the Venous thromboEmbolism
Network US). The institutional review board at each participating
hospital approved the protocol, and all patients provided written
informed consent before study procedures. Eligible patients were
$18 years of age with histologically conﬁrmed active malignancy,
deﬁned as a cancer diagnosis or having received cancer-directed
therapy within 6 months of study enrollment. Patients were required
to have radiologically conﬁrmed VTE and concurrent thrombocytopenia with a platelet count ,100 000/mL within 72 hours of VTE
diagnosis (either before or after VTE diagnosis). Patients were
required to enroll within 7 days of VTE diagnosis. The initial anticoagulation strategy was obtained from the medical chart and classiﬁed
as either full dose with platelet transfusion support, modiﬁed
dose (eg, unfractionated heparin with decreased activated partial

A total of 121 patients were enrolled (Table 1) from March 2018 to
August 2020. The majority of patients (n 5 75 [62%]) were treated
with full-dose anticoagulation and 33 (27%) patients with modiﬁeddose anticoagulation; 13 (11%) patients received no anticoagulation. Baseline characteristics differed between the treatment cohorts
in some aspects. A greater proportion of patients with hematologic
malignancies initially received modiﬁed-dose anticoagulation,
whereas patients with solid tumors predominantly received full-dose
anticoagulation. Of the 45 patients enrolled with qualifying pulmonary emboli, 80% received full-dose anticoagulation. Among the
101 patients enrolled with deep vein thrombosis (DVT), 59%
received full-dose anticoagulation, 38% received modiﬁed-dose anticoagulation, and 12% were not anticoagulated. A total of 48
patients had index upper extremity DVT, 38 (79%) of which were
catheter associated. Low-molecular-weight heparin (LMWH) was
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Thrombocytopenia is common in cancer, either due to the underlying disease or as a side effect of antineoplastic therapy. In hematologic malignancies, which are frequently associated with VTE,
platelet counts often decline to ,50 000/mL.5 A retrospective
cohort study of 2537 patients with hematologic malignancies
reported a 28% incidence of thrombocytopenia to ,100 000/mL,
with 16% of patients experiencing platelet counts ,50 000/mL.6
Certain chemotherapeutics used in the treatment of solid tumors
such as gemcitabine and platinum-based agents are frequently
associated with thrombocytopenia (30%-50% incidence), with
platelet counts ,50 000/mL occurring in 5% to 10% of patients.7,8
The appropriate management of acute VTE and thrombocytopenia
is uncertain. Treatment guidelines include recommendations regarding the administration of full therapeutic or modiﬁed-dose anticoagulation, with or without target platelet transfusion goals.9,10 The
relative safety or efﬁcacy of these approaches has not been established. In a retrospective cohort study of 1514 patients undergoing
allogeneic stem cell transplantation at John Hopkins Hospital,
approximately one-third of patients experienced a hemorrhage when
full-dose anticoagulation was administered along with platelet transfusion support.11 Other studies have similarly suggested a high rate
of hemorrhage as well as recurrent VTE in this patient population
when treated with full-dose anticoagulation.4 A retrospective quality
assurance project conducted at Memorial Sloan Kettering Cancer
Center identiﬁed modiﬁed-dose anticoagulation as a potentially safer
alternative to full-dose anticoagulation in the setting of severe
thrombocytopenia.12

thromboplastin time or anti–factor Xa targets, enoxaparin dose
,1.5 mg/kg per 24 hours, 2.5 mg apixaban twice daily, or 10 mg
rivaroxaban daily), or not started.

Table 1. Baseline characteristics
Characteristic
Male sex, n (%)

Full-dose
(n 5 75)

Modiﬁed-dose
(n 5 33)

None
(n 5 13)

16 (48)

10 (77)

60 (26-78)

65 (42-78)

70 (93)

30 (91)

11 (85)

Hematologic malignancy

43 (57)

31 (94)

11 (85)

Solid tumor

32 (43)

2 (6)

2 (15)

38 (51)

15 (45)

7 (54)

0

2 (6)

1 (8)

Cirrhosis

2 (3)

0

0

History of major hemorrhage

2 (3)

0

0

Brain metastases

7 (9)

0

1 (8)

7.4 (7.0-8.7)

Inpatient, n (%)
Cancer diagnosis, n (%)

Comorbidities, n (%)
Hypertension
Chronic kidney disease

Median baseline laboratory values (IQR)
Hemoglobin, g/dL

8.7 (7.4-10.7)

7.9 (7.5-9.7)

Platelet count, K/mL

65 (47-88)

37 (24-48)

16 (14-32)

Prothrombin time, s

14.1 (13-15.3)

13 (12.1-13.8)

13.8 (13.5-14.6)

Creatinine, mg/dL

0.8 (0.6-1.0)

0.8 (0.5-1.1)

0.8 (0.7-1.8)

Total bilirubin, mg/dL

0.6 (0.4-1.1)

0.5 (0.4-0.7)

0.8 (0.5-0.9)

During the study follow-up period, changes in anticoagulant prescribed were frequent. In 26 patients who initially received unfractionated heparin, 9 patients switched to LMWH and 8 switched to a
DOAC. An additional 15 patients were switched from LMWH to a
DOAC during follow-up. Changes in anticoagulation intensity
occurred much less frequently, with 3 patients switching from
modiﬁed-dose to full-dose anticoagulation and 4 patients switching
from full-dose to modiﬁed-dose anticoagulation during follow-up.
Among 134 follow-up visits in patients initiated on full-dose anticoagulation, 127 (94.8%) were characterized as having excellent adherence to the documented anticoagulation strategy (ie, appropriate
dose adjustments and/or administration of platelet transfusion
support based on threshold platelet counts). Similarly, in the
modiﬁed-dose anticoagulation cohort, 49 (89.1%) of 55 visits were
characterized as excellent adherence. There was no difference in
quality of adherence between the full-dose and modiﬁed-dose anticoagulation cohorts (P 5 .21).

Hemorrhage

Index VTE event

the most common anticoagulant used for both full-dose and
modiﬁed-dose anticoagulation. A total of 16 patients were initially
started on a direct oral anticoagulant (DOAC), with 13 receiving
apixaban and 3 rivaroxaban. In patients started on full-dose anticoagulation with platelet transfusion support, the platelet transfusion
threshold ranged from 10 000 to 50 000/mL. The most common
transfusion threshold was a platelet count ,50 000/mL (74%).
In patients started on modiﬁed-dose anticoagulation, the most
common dose modiﬁcation strategy was half-dose enoxaparin
(0.5 mg/kg every 12 hours).

There were 23 hemorrhagic events during the 60-day study period
(Table 2). Eighteen of the hemorrhagic events occurred in patients
who initially received full-dose anticoagulation, and the remaining 5
occurred in patients started on modiﬁed-dose anticoagulation. The
cumulative incidence of total hemorrhage at 60 days was 24%
(95% conﬁdence interval [CI], 13.9-34.1) in patients who initially
received full-dose anticoagulation compared with 15.9% (95% CI,
2.8-28.9) in the modiﬁed-dose anticoagulation group. In patients
who initially received full-dose anticoagulation, the cumulative incidence of major hemorrhage at 60 days was 12.8% (95% CI, 4.920.8) compared with 6.6% (95% CI, 2.4-15.7) in the modiﬁed-dose
anticoagulation group (Fine-Gray hazard ratio, 2.18; 95% CI, 1.213.93) (Figure 2). Four of the ﬁve patients initially started on
modiﬁed-dose anticoagulation who subsequently experienced a
hemorrhage were receiving full-dose anticoagulation at the time of
the event. Of the 11 total major hemorrhagic events, only 1 patient
was receiving modiﬁed-dose anticoagulation at the time of the
bleed. One fatal hemorrhage (an upper gastrointestinal hemorrhage)
occurred in a patient on full-dose anticoagulation. There were no
hemorrhagic events in the cohort receiving no anticoagulation.
Among the 11 patients who experienced a major hemorrhage, the
median time from index VTE to major hemorrhage was 20 days in
patients started on full-dose anticoagulation and 50.5 days in
patients started on modiﬁed-dose anticoagulation.

The median platelet count was higher in patients who were initially
started on full-dose anticoagulation, with a median of 65 000/mL
compared with 37 000/mL in the modiﬁed-dose anticoagulation
cohort (P , .001). The median platelet count was 16 000/mL in the
group that received no anticoagulation. During follow-up, platelet
count nadir at 30 days remained signiﬁcantly lower in patients
treated with modiﬁed-dose anticoagulation (26 000/mL; P 5 .02)
and no anticoagulation (8000/mL; P , .001) than those receiving
full-dose anticoagulation (42 000/mL). The distribution of duration of

Recurrent VTE. There were 5 recurrent VTE events (Table 3).
Four occurred in patients who initially received full-dose anticoagulation and 1 occurred in a patient who did not receive anticoagulation.
No patient who initially received modiﬁed-dose anticoagulation experienced a recurrent VTE. The cumulative incidence of recurrent VTE
at 60 days in patients who initially received full-dose anticoagulation
was 5.6% (95% CI, 0.2-11) and 0% in patients who initially
received modiﬁed-dose anticoagulation (Figure 2).

Proximal lower extremity DVT

19 (25)

6 (18)

2 (15)

Distal lower extremity DVT

14 (19)

6 (18)

2 (15)

Upper extremity DVT

23 (31)

17 (81)

8 (62)

Pulmonary embolism

36 (48)

7 (21)

2 (15)

4 (5)

0

0

LMWH

40 (53)

26 (79)

0

Unfractionated heparin

23 (31)

3 (9)

0

Direct oral anticoagulant

12 (16)

4 (12)

0

Mesenteric thrombosis
Anticoagulant, n (%)

IQR, interquartile range.
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39 (52)
59 (23-88)

Mean age at enrollment (range), y

thrombocytopenia over 60-day follow-up in the full-dose and
modiﬁed-dose cohorts is shown in Figure 1. The mean duration of
severe thrombocytopenia (platelet count #50 000/mL) was 9.73
days in the full-dose cohort and 13.76 days in the modiﬁed-dose
cohort (P 5 .07).

B

Full dose

Modified dose
40

30

30

Days

40

20

10

0

20
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A
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0
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10—25

25—50
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Platelet count

25—50

50—100

Platelet count

Figure 1. Duration and severity of thrombocytopenia. Duration of thrombocytopenia in patients receiving full-dose (A) or modiﬁed-dose (B) anticoagulation.

A
Full dose

0.20

Cumulative incidence

Modified dose

0.15
0.10
0.05
0.00
0

10
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Time (days)

B
Full dose

0.20

Cumulative incidence

Modified dose

0.15
0.10
0.05
0.00
0

10

20

30

40

50

60

Time (days)
Figure 2. Major hemorrhage and recurrent VTE. Cumulative incidence of major hemorrhage (A) and recurrent VTE (B) according to initial anticoagulation regimen. Fulldose (blue); modiﬁed dose (red).

28 DECEMBER 2021 • VOLUME 5, NUMBER 24

ANTICOAGULATION IN CAT WITH THROMBOCYTOPENIA

5549

Table 2. Hemorrhagic events during the 60-day study period
according to initial anticoagulation strategy
Hemorrhage characteristics
Total hemorrhage, n (%)

Table 3. Recurrent VTE events during the 60-day study period
according to initial anticoagulation strategy

Full-dose Modiﬁed-dose None
(n 5 75)
(n 5 33)
(n 5 13)
18 (24)

5 (15)

0

Severity of hemorrhage, n (%)

VTE characteristics
Total recurrent VTE events

Full-dose
(n 5 75)

Modiﬁed-dose
(n 5 33)

None
(n 5 13)

4 (5)

0

1 (8)

0

Recurrent VTE event

Fatal hemorrhage

1 (1)

0

0

Distal lower extremity DVT

1 (1)

0

Major hemorrhage

8 (11)

2 (6)

0

Proximal lower extremity DVT

2 (3)

0

0

Clinically relevant nonmajor hemorrhage

9 (12)

2 (6)

0

Upper extremity DVT

0

0

1 (8)

0

1 (3)

0

Pulmonary embolism

1 (1)

0

0

Minor hemorrhage

Intracranial hemorrhage
Ocular

Anticoagulant dose at time of recurrent VTE
2 (3)

1 (3)

0

Full-dose

0

1 (3)

0

Modiﬁed-dose

Upper gastrointestinal bleed

1 (1)

0

0

Lower gastrointestinal bleed

7 (9)

1 (3)

0

None

2 (3)

0

0

0

0

0

2 (3)

0

1 (8)

Anticoagulant at time of recurrent VTE

Retroperitoneal

1 (1)

0

0

LMWH

1 (1)

0

0

Hematuria

4 (5)

0

0

Unfractionated heparin

1 (1)

0

0

Mucocutaneous

4 (5)

2 (6)

0

Direct oral anticoagulant

0

0

0

Intramuscular

1 (1)

0

0

Anticoagulant dose at time of hemorrhage
15 (20)

4 (12)

—

Modiﬁed-dose

3 (4)

1 (3)

—

None

1 (1)

0

—

Full-dose

Anticoagulant at time of hemorrhage
10 (13)

2 (6)

—

Unfractionated heparin

4 (5)

1 (3)

—

Direct oral anticoagulant

4 (5)

2 (6)

—

20

16

20

LMWH

Median days with platelet count ,100 000/mL

Among the 5 patients who experienced recurrent VTE, the median
time from index VTE to recurrence was 19 days. Recurrent VTE
events included a segmental pulmonary embolism in a patient who
initially had only an upper extremity DVT, an upper extremity DVT,
2 proximal lower extremity DVTs, and a distal lower extremity DVT.
Three of ﬁve patients were receiving full-dose heparin anticoagulation at the time of recurrent VTE. The other 2 patients were not
receiving anticoagulation at the time of recurrent VTE due to prolonged thrombocytopenia in one case and a recent retroperitoneal
hemorrhage in another. A single patient who was initially not started
on anticoagulation developed a recurrent VTE. The index event was
an upper extremity DVT. Propagation of the upper extremity DVT
was noted 11 days after initial recognition, prompting the initiation
of full-dose anticoagulation.
Hemorrhage and thrombosis during exposure to DOACs.
A total of 16 patients were initially started on a DOAC (15 patients
starting full-dose anticoagulation and 1 modiﬁed-dose anticoagulation) and 27 were switched to a DOAC during follow-up. Of the
patients started on a DOAC, 2 had luminal gastrointestinal malignancies, and 1 had bladder cancer. The median platelet count at
the time of DOAC initiation was 51 000/mL (range, 12 000-98 000/
mL). Among patients initially started on a DOAC, median exposure
to the DOAC was 62 days, with only 1 patient switching to LMWH
5550
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during follow-up. Three hemorrhagic events occurred in patients initially started on a DOAC during the 60-day follow-up period, correlating to a cumulative incidence of hemorrhage of 20% (95% CI, 040). Two of these events were lower gastrointestinal hemorrhage
adjudicated as major hemorrhages. All 3 events occurred while on a
full-dose DOAC. An additional 3 hemorrhagic events occurred in
patients switched to a DOAC during follow-up. The events included
a lower gastrointestinal hemorrhage and 2 patients with hematuria.
All were adjudicated as clinically relevant nonmajor bleeding. There
were no recurrent VTE events in patients who were initially started
on and/or were actively receiving a DOAC.

Survival
A total of 22 patients died during the 60-day follow-up period.
Median survival was not reached in either cohort. Survival at
60 days was 81.5% in the full-dose anticoagulation cohort and
80.1% in the modiﬁed-dose anticoagulation cohort (log-rank test,
P 5 .90).

Discussion
Anticoagulation management in patients with cancer who develop
VTE in the setting of thrombocytopenia is challenging given the
high risk of hemorrhage balanced against the risk of recurrent
thrombosis. Retrospective studies suggested that modiﬁed-dose
anticoagulation is a viable alternative to full-dose anticoagulation
with platelet transfusion support.11,12 In the TROVE (Thrombocytopenia Related Outcomes with Venous thromboEmbolism) study,
we observed a lower rate of major hemorrhage in patients with
thrombocytopenia and VTE initially treated with modiﬁed-dose
anticoagulation relative to those initially managed with full-dose
anticoagulation. The rates of recurrent VTE were low in both
cohorts.
To the best of our knowledge, this analysis represents the ﬁrst prospective study assessing the rates of hemorrhage and recurrent
28 DECEMBER 2021 • VOLUME 5, NUMBER 24
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Type of hemorrhage

There were very few recurrent VTE events documented in this study.
This stands in contrast to some retrospective studies that have
reported rates of recurrent thrombosis in excess of 40%.4,18 The
observation period in the current study was 60 days, which may
account for the lower rates of recurrent VTE observed. All thrombotic events were centrally adjudicated with clear criteria for progression or recurrence. Although this study was underpowered to
conclude that the 2 anticoagulation approaches were similarly effective, there were no cases of recurrent or progressive VTE among
patients initially receiving modiﬁed-dose anticoagulation.
Because anticoagulation management was not randomized in
this study, not unexpectedly, there were baseline imbalances,
including more patients with pulmonary emboli receiving full-dose
anticoagulation. There are limited prospective data available
showing the efﬁcacy of modiﬁed-dose anticoagulation in higher
risk VTE, and guidance from the International Society on Thrombosis and Haemostasis is full-dose anticoagulation with platelet
transfusion support in patients with severe thrombocytopenia
and a high risk of thrombus progression such as pulmonary
embolism and proximal lower extremity DVT.10 With only 7
patients with pulmonary embolism receiving modiﬁed-dose anticoagulation, we were unable to conclude that modiﬁed-dose anticoagulation is an effective strategy for this indication, although
none of the 7 patients developed recurrent VTE during the
60-day follow-up. A prior study included 26 patients with pulmonary emboli treated with modiﬁed-dose anticoagulation, and none
developed recurrent or progressive VTE.12
The 2 cohorts were also imbalanced according to underlying
cancer diagnosis. Almost all patients in the modiﬁed-dose arm
carried a hematologic malignancy diagnosis compared with
57% in the full-dose anticoagulation arm. Accordingly, the
severity of thrombocytopenia, both in terms of depth and duration of thrombocytopenia, was more pronounced in the
modiﬁed-dose anticoagulation arm compared with the full-dose
anticoagulation arm. As such, the modiﬁed-dose anticoagulation
arm represented a higher hemorrhagic risk population relative to
the full-dose anticoagulation arm. Despite this imbalance, there
were no major hemorrhages observed in those patients who
received modiﬁed-dose anticoagulation, providing additional
reassurance regarding the safety of this approach during periods of thrombocytopenia.
In the TROVE study, patients received anticoagulation at the discretion of the treating clinician. Although patients were prospectively
followed up, a treatment regimen was not prescribed per a deﬁned
28 DECEMBER 2021 • VOLUME 5, NUMBER 24

protocol. Qualitative treatment adherence assessments were performed at study visits, and overall the adherence to the prescribed
anticoagulation strategy was classiﬁed as excellent. However, this
study was not designed to validate a speciﬁc anticoagulant or dosing regimen. Criteria for modiﬁed-dose anticoagulation was below
therapeutic dosing (ie, LMWH ,1.5 mg/kg daily), with the most
common regimen being LMWH according to the treatment plan
described by Mantha et al.12 For initial treatment of VTE, the most
common therapeutic and modiﬁed-dose anticoagulation regimen
was LMWH. Although transition from full-dose to modiﬁed-dose
anticoagulation or vice versa was uncommon, several patients
switched to alternative therapeutic anticoagulants (eg, unfractionated heparin to full-dose LMWH).
DOACs have established efﬁcacy relative to LMWH for the treatment of cancer-associated thrombosis, although there is concern for
increased rates of bleeding in luminal gastrointestinal and possible
genitourinary and gynecologic malignancies.19-21 The phase 3 randomized trials had different eligibility platelet cutoffs ranging
between 50 000/mL and 100 000/mL. In these studies, very few
patients were enrolled with platelet counts ,100 000/mL, and outcomes during periods of thrombocytopenia have not been
described. Our study represents the largest experience to date with
DOACs in patients with cancer-associated thrombosis and thrombocytopenia. In our study, 6 of the 23 hemorrhagic events occurred
in patients receiving a DOAC at the time of the event. As such, the
safety of DOACs during periods of thrombocytopenia remains
unclear, and additional data are required.
Although full-dose anticoagulation with platelet transfusion support
seems to be the most common treatment strategy for the management of VTE associated with thrombocytopenia in our study, it
poses challenges both conceptually and practically. The justiﬁcation
of supplementing platelets on the backdrop of an existing thrombus
to permit full-dose anticoagulation is largely theoretical. Transfusion
of platelets in this setting has been associated with an increased
risk of thrombosis.22 Aggressive platelet transfusion poses additional challenges and potential complications (including transfusion
reactions and allo-immunization in a heavily transfused population),23,24 somewhat arbitrary transfusion thresholds, and intense
resource utilization. A modiﬁed-dose anticoagulation strategy without
platelet transfusion targets addresses some of these issues and permits a degree of anticoagulation ﬁne-tuning based on severity of
thrombocytopenia.
A key limitation of this study was its lack of randomization for treatment allocation and the imbalanced baseline characteristics in both
arms, which could inﬂuence outcomes. The adherence to the documented anticoagulation strategy (including platelet transfusion management) was determined by local investigators and not centrally
adjudicated. Strengths of this study include enrollment of patients at
multiple centers nationally, prospective data collection, and central
adjudication of all qualifying hemorrhagic or thrombotic events.
In conclusion, the TROVE study showed that in select patients with
cancer who develop VTE in the setting of thrombocytopenia,
modiﬁed-dose anticoagulation was well tolerated with a low rate of
recurrent VTE. In the setting of DVT, this study adds to the accumulating data that modiﬁed-dose anticoagulation seems to be both efﬁcacious and safe during periods of thrombocytopenia.
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thrombosis according to anticoagulation strategy in patients with
thrombocytopenia at the time of VTE. The reported rates of hemorrhage with modiﬁed-dose anticoagulation in smaller single-institution
cohorts are highly variable, ranging from 0% to 33%.4,12,16,17 Retrospective comparisons of hemorrhagic outcomes between the 2 anticoagulation strategies generally show favorable hemorrhagic
outcomes with modiﬁed-dose anticoagulation.4,16,18 In this study,
the absence of major hemorrhage at 30 days with modiﬁed-dose
anticoagulation provides prospective evidence that this approach
seems safe in the management of DVT in the setting of thrombocytopenia. The substantial rates of major hemorrhage observed in both
cohorts by 60 days’ follow-up highlight the high-risk nature of this
patient population and the need for prospective data to inform clinical decision-making.
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